Company Description
Catalent Pharma Solutions, Inc. provides development solutions and delivery technologies for drugs, biologics, and consumer health products.
The company’s Development and Clinical Services segment offers manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials.
This segment also provides analytical chemical and cell-based testing and scientific services; respiratory products formulation and manufacturing; regulatory consulting; and bioanalytical testing for biologic products.
Its Oral Technologies segment offers oral delivery technologies, including formulation, development, and manufacturing services for the oral dose forms comprising prescription and consumer health products.
This segment provides formulation, development, and manufacturing services for soft gelatin capsules, modified release, and immediate release solid oral technology products; and fast-dissolve tablets, and proprietary and conventional controlled release products.
The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for prefilled syringes and other injectable formats; blow-fill-seal unit dose development and manufacturing services; and biologic cell line development and manufacturing services.
It serves pharmaceutical and biotechnology, and consumer health companies. The company was incorporated in 1989 and is headquartered in Somerset, New Jersey.
Catalent Pharma Solutions, Inc. operates as a subsidiary of Catalent, Inc.
| Country | United States |
| Founded | 1989 |
| IPO Date | Jul 31, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 17,800 |
| CEO | Alessandro Maselli |
Contact Details
Address: 14 Schoolhouse Road Somerset, Delaware 08873 United States | |
| Phone | 732 537 6200 |
| Website | catalent.com |
Stock Details
| Ticker Symbol | CTLT |
| Exchange | NYSE |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001596783 |
| CUSIP Number | 148806102 |
| ISIN Number | US1488061029 |
| Employer ID | 20-8737688 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alessandro Maselli | President, Chief Executive Officer and Director |
| John J. Greisch M.B.A. | Executive Chairman of the Board |
| Matti M. Masanovich | Senior Vice President and Chief Financial Officer |
| Lisa Evoli | Senior Vice President and Chief Human Resources Officer |
| Ricky Hopson | President, Division Head for BioProduct Delivery and Chief of Staff |
| David McErlane | Group President of Biologics Segment |
| Michael J. Hatzfeld Jr. | Vice President and Chief Accounting Officer |
| Charles Lickfold | Senior Vice President and Chief Information Officer |
| Paul Surdez | Vice President of Investor Relations |
| Joseph A. Ferraro J.D. | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | POSASR | Filing |
| Dec 18, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 18, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 18, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Dec 18, 2024 | 8-K | Current Report |
| Dec 18, 2024 | 25-NSE | Filing |
| Dec 16, 2024 | 8-K | Current Report |
| Dec 6, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |